A breakthrough approach to early detection

Adela is focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test.

science

The DNA methylome is a rich source of information about human disease. Adela’s genome-wide methylome enrichment platform uniquely captures information efficiently from the entire methylome. 

Adela’s technology distinguishes the most-highly informative (methylated) regions of the genome from non-informative regions and preferentially targets those regions for sequencing. 

In addition, Adela’s technology does not require bisulfite conversion, which is a chemical treatment that causes loss of valuable genomic material and information. 

Adela's technology leverages machine learning to detect and classify underlying disease, including tissue of origin and histologic subtype. 

publications

Sensitive tumour detection and classification using plasma cell-free DNA methylomes

read more

Detection of renal cell carcinoma using plasma and urine cell-free DNA methylomes

read more

Detection and discrimination of intracranial tumors using plasma cell-free DNA methylomes

read more

Preparation of cfMeDIP-seq libraries for methylome profiling of plasma cell-free DNA

read more

Tumor-naïve multimodal profiling of circulating tumor DNA in head and neck squamous cell carcinoma

read more

Press

Adela Initiates Key Study for Cancer Early Detection Program

Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has enrolled the first participant in a multi-center study supporting the development and validation of its genome-wide methylome enrichment platform for the early detection of cancer.

Adela Announces Executive and Board of Directors Appointments and Formation of Scientific Advisory Board

Adela, Inc., focused on the detection of cancer and other high-morbidity, high-mortality conditions through a blood test, has made appointments to the Executive Team and Board of Directors that add to the deep industry and scientific expertise of the current team. The company has also formed a Scientific Advisory Board comprised of renowned scientists and clinicians. 

Adela Debuts with $60M in Series A Financing and a Breakthrough Approach to Blood-Based Detection of Cancer and Other Diseases

Adela’s technology detects signals of early disease with high sensitivity through efficient mining of the entire methylome